GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (NYSE:COR) » Definitions » Capex-to-Operating-Cash-Flow

Cencora (Cencora) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Cencora Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Cencora's Capital Expenditure for the three months ended in Mar. 2024 was $-112.75 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $-878.44 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Cencora Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Cencora's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cencora Capex-to-Operating-Cash-Flow Chart

Cencora Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.17 0.16 0.18 0.12

Cencora Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.14 0.10 0.08 -

Competitive Comparison of Cencora's Capex-to-Operating-Cash-Flow

For the Medical Distribution subindustry, Cencora's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cencora's Capex-to-Operating-Cash-Flow Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cencora's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cencora's Capex-to-Operating-Cash-Flow falls into.



Cencora Capex-to-Operating-Cash-Flow Calculation

Cencora's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Sep. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-458.359) / 3911.334
=0.12

Cencora's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-112.753) / -878.443
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cencora  (NYSE:COR) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Cencora Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cencora's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cencora (Cencora) Business Description

Traded in Other Exchanges
Address
1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Executives
Leslie E Donato officer: EVP & Chief Strategy Officer 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Elizabeth S Campbell officer: Executive Vice President 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Steven H Collis officer: President & CEO 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Lazarus Krikorian officer: Senior Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Silvana Battaglia officer: Executive Vice President 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Walgreens Boots Alliance, Inc. 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Gina Clark officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Werner Baumann director 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Lauren M Tyler director C/O ALLEGHANY CORPORATION, 1411 BROADWAY, 34TH FLOOR, NEW YORK NY 10018
Robert P. Mauch officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Redonda Miller director 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Lorence H. Kim director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Walgreens Boots Alliance Holdings Llc 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Lon R Greenberg director 460 NORTH GULPH ROAD, KING OF PRUSSIA PA 19406
John G. Chou officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087

Cencora (Cencora) Headlines

From GuruFocus

Q3 2021 Amerisourcebergen Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Amerisourcebergen Corp Investor Day Transcript

By GuruFocus Research 01-22-2024

Cencora Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Amerisourcebergen Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Amerisourcebergen Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Amerisourcebergen Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Amerisourcebergen Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024